Bill Wilson argues GLP-1 drugs work as a master switch for insulin resistance, the root cause of metabolic syndrome. They're far more effective than older drugs like metformin at preventing cardiovascular disease and kidney damage by fixing the underlying metabolic dysfunction.
Chapters
Recent studies of these drugs suggest that these medications could save thousands of lives annually. Could you expand the broader health benefit, such as reducing. There's a conversation about cardiovascular risk and there's chronic kidney disease risk. How does that work? What's the relations between now GLP1 and cardiovascular and kidney disease?
They're right at the floodgate of chronic diseases in our modern society. Almost all of those diseases are tied into insulin resistance and metabolic problems. And so these drugs directly impact that in a positive way that, that we don't. We, you know, in the past, we've had metformin and, you know, bunch of other things that, you know, that that's the best we had. But they, they're Nothing like the GLPs. This is like the master switch they found.